<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">Antiphospholipid syndrome</z:e> (APS) carries a risk of <z:mp ids='MP_0005048'>thrombosis</z:mp> and <z:hpo ids='HP_0000789'>infertility</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Consequently the use of any type of hormone therapy and pregnancy in APS requires special considerations </plain></SENT>
<SENT sid="2" pm="."><plain>The present article provides a broad review of <z:hpo ids='HP_0000001'>all</z:hpo> these issues </plain></SENT>
<SENT sid="3" pm="."><plain>The use of contraception, hormone replacement therapy and selective <z:chebi fb="0" ids="50739">estrogen receptor modulators</z:chebi> in APS are described </plain></SENT>
<SENT sid="4" pm="."><plain>In vitro fertilization/embryo transfer and ovarian induction in these patients are reviewed </plain></SENT>
<SENT sid="5" pm="."><plain>Lastly, the possible fetal and maternal complications that can occur during pregnancy are described and, based on the literature, recommendations for the management of pregnancy in women with APS are provided </plain></SENT>
</text></document>